medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2021, Number 2

<< Back Next >>

Acta Ortop Mex 2021; 35 (2)

Comparative study between enoxaparin and salicylic acetyl acid in antithrombotic prophylaxis for patients undergoing total knee arthroplasty

Cortes-De FA, Villalobos-Campuzano C, Bucio-Paticio B, Valencia-Martínez G, Martínez-Montiel O

Language: Spanish
References: 18
Page: 163-168
PDF size: 141.58 Kb.


ABSTRACT

Introduction: There is still controversy regarding thrombo-prophylaxis for the reduction of thromboembolic disease in major orthopedic surgery. Objective: To answer the following question: is there a difference in the effectiveness and safety in the antithrombotic management of patients with a traditional regimen of enoxaparin against acetyl salicylic acid? Material and methods: The surgeries were performed by 3 surgeons; the sample was randomized and the patients were subjected to the study criteria. We evaluated efficacy and safety as well as the need for readmission and secondary variables such as infection, acute myocardial infarction (AMI), cerebral vascular disease and death with a follow-up of 90 days. Results: The total sample was 402 patients; 214 in the enoxaparin group and 188 in the aspirin group. There were 5 cases (1.24%) with thromboembolic disease, 3 (1.4%) enoxaparin and 2 (1.06%) aspirin without significant difference (p = 0.23). In terms of safety, major bleeding was zero in both groups, with minor bleeding in 7 patients (1.74%), 4 (1.86%) were from the enoxaparin group and 3 (1.59%) from the aspirin group without significant differences (p = 0.82). Secondary outcomes showed 5 (1.24%) superficial surgical wound infections and one AMI in the first 30 days of the procedure in the enoxaparin group. Conclusion: Aspirin as monotherapy is safe, effective in antithrombotic prophylaxis in patients operated on total knee arthroplasty.


REFERENCES

  1. Azboy I, Barrack R, Thomas AM, Haddad FS, Parvizi J. Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions. Bone Joint J. 2017; 99-B(11): 1420-30. doi: 10.1302/0301-620X.99B11.BJJ-2017-0337.R2.

  2. Lussana F, Squizzato A, Permunian ET, Cattaneo M. A systematic review on the effect of aspirin in the prevention of post-operative arterial thrombosis in patients undergoing total hip and total knee arthroplasty. Thrombosis Research. 2014; 134(3): 599-603. doi: 10.1016/j.thromres.2014.06.027.

  3. Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J. 2004; 80(941): 155-64. doi: 10.1136/pgmj.2003.007062.

  4. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000; 101(10): 1206-18. doi: 10.1161/01.cir.101.10.1206.

  5. Jenny JY, Pabinger I, Samama CM; ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin. Eur J Anaesthesiol. 2018; 35(2): 123-129. doi: 10.1097/EJA.0000000000000728.

  6. An VV, Phan K, Levy YD, Bruce WJ. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty. 2016; 31(11): 2608-16. doi: 10.1016/j.arth.2016.04.004.

  7. Lieberman JR, Heckmann N. Venous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: from guidelines to practice. J Am Acad Orthop Surg. 2017; 25(12): 789-98. doi: 10.5435/JAAOS-D-15-00760.

  8. Gutowski CJ, Zmistowski BM, Lonner JH, Purtill JJ, Parvizi J. Direct costs of aspirin versus warfarin for venous thromboembolism prophylaxis after total knee or hip arthroplasty. J Arthroplasty. 2015; 30(9 Suppl): 36-8. doi: 10.1016/j.arth.2015.04.048.

  9. Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013; 158(11): 800-6. doi: 10.7326/0003-4819-158-11-201306040-00004.

  10. Lieberman J, Berry D, Azar F. Advanced reconstruction knee. Rosemont, IL: American Academy of Orthopaedic Surgeons (AAOS); 2011.

  11. Azboy I, Groff H, Goswami K, Vahedian M, Parvizi J. Low-dose aspirin is adequate for venous thromboembolism prevention following total joint arthroplasty: a systematic review. J Arthroplasty. 2020; 35(3): 886-92. doi: 10.1016/j.arth.2019.09.043.

  12. Mostafavi Tabatabaee R, Rasouli MR, Maltenfort MG, Parvizi J. Cost-effective prophylaxis against venous thromboembolism after total joint arthroplasty: warfarin versus aspirin. J Arthroplasty. 2015; 30(2): 159-64. doi: 10.1016/j.arth.2014.08.018.

  13. Harenberg J, Jorg I, Fenyvesi T. Heparin-induced thrombocytopenia: pathophysiology and new treatment options. Pathophysiol Haemost Thromb. 2002; 32(5-6): 289-94. doi: 10.1159/000073583.

  14. Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med. 2012; 367(21): 2039-41. doi: 10.1056/NEJMe1211480.

  15. Wendelboe AM, St Germain L, Krolak B, Reiser T, Raskob G; ISTH Steering Committee on World Thrombosis Day. Impact of world thrombosis day campaign. Res Pract Thromb Haemost. 2017; 1(1): 138-41.

  16. Wolberg AS, Rosendaal FR, Weitz JI, Jaffer IH, Agnelli G, Baglin T, et al. Venous thrombosis. Nat Rev Dis Primers. 2015; 1: 15006.

  17. Bang SM, Jang MJ, Kim KH, Yhim HY, Kim YK, Nam SH, et al. Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice Guidelines. J Korean Med Sci. 2014; 29(2): 164-71.

  18. Buesing KL, Mullapudi B, Flowers KA. Deep venous thrombosis and venous thromboembolism prophylaxis. Surg Clin North Am. 2015; 95(2): 285-300.



EVIDENCE LEVEL

II, Estudio prospectivo comparativo.




2020     |     www.medigraphic.com